Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
To compare the sequential administration of exemestane with administration of further
tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already
received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall
survival (OS), incidence of contralateral breast cancer and long-term tolerability.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Collaborators:
International Collaborative Cancer Group International Collaborative Cancer Group (ICCG)